Developed with Aprecia’s proprietary 3DP manufacturing process, ZipDose® Technology helps patients who need medicines that are easy to take and caregivers—including physicians and nurse practitioners—who want medicines that are easy to administer. By enabling delivery of high-dose medications in a rapidly disintegrating form, ZipDose overcomes patient adherence and difficulty swallowing challenges.
Hanningfield’s Uni-Mill conical screen mill can be designed to be a completely closed system, through the incorporation of split butterfly valves, a closed loop vacuum transfer system, or glove box milling.
Sensitive products, such as glass ampoules and syringes, require especially gentle and safe product handling, and a high degree of pack style flexibility. Our flexible cartoning solutions ensure that your products are securely packaged, in vertical or horizontal position or in multiple layers, with or without product holder. In addition, we offer optional versions with various opening aids, reclosure functions as well as tamper evidence applications. Product information and/or package inserts can be included in the carton box.
For 50 years, WIRB-Copernicus Group has stood as the gold standard of ethical and regulatory human research oversight, with more years of IRB and IBC experience and more deep, trusted relationships with sponsors, CROs, institutions, and investigators.
YPrime’s IRT+ goes beyond traditional IRT capabilities of patient randomization and drug supply management with control and a real-time view into critical functions and flows of a clinical trial - involving patient interactions, site activities and clinical supply management.
Advancements in technology are moving more quickly today than ever before, making it difficult for insurance organizations to keep up. As the industry evolves, it has become more apparent that insurers are only as good as the data utilized throughout their decision-making processes. Organizations must take a closer look at their internal operating workflows such as claims processing and embrace emerging technologies to streamline traditional workflows that can no longer adapt to the current or future consumer demands of the industry.
With each clinical research initiative bringing its own set of requirements and challenges to the table, leveraging a technology solution that’s flexible enough to work the way you need it to is beneficial.
Improve quality of care through a pediatric specific EHR technology
The objective of this study was to compare the equivalence of a new version of the electronic Columbia-Suicide Severity Rating Scale that was administered on a tablet device. The results supported the validity and reliability of the new tablet-based electronic Columbia-Suicide Severity Rating Scale and allow its inclusion in a wider range of clinical studies, particularly where a tablet is also being used to collect other study data.
The CRO realized that they needed to introduce new ways to keep participants engaged and interested if they were going to successfully support this trial. The CRO identified ClinCard as the ideal software that could instantly get study participants their stipends, without adding a burden on the site staff.
Once deemed an “experts-only” approach to chemical synthesis, flow chemistry is a cost-efficient technique growing in popularity that can increase safety and flexibility and improve product quality.
To address the growing need for speed and efficiency in viral vector manufacturing, GE developed a process for adenovirus manufacturing that not only meets regulatory requirements but is also scalable.
Like every other POS provider in the United States, NCR found itself in 2014 facing an upcoming EMV liability shift that had many of its merchants in a state of panic. Mark Critchett, product management director, small business division for NCR Corp. recalls the pressure felt industry-wide to get technology in place that would enable EMV payments. For NCR, that meant addressing EMV for both its NCR Silver and NCR Silver Pro Restaurant Edition software.
Change the perception of clinical trials by making them less burdensome for patients overall.
Beginning around 2007, traditional endpoint security was becoming ineffective. Stopping infections was based around finding a user with an infection (patient zero), creating a detection signature (inoculation) and then updating every device to stop any further infections (eradication). The ineffectiveness was a direct result of the volume, variety, and velocity of infections. These factors completely overwhelmed the ‘patient zero’ approach. There were simply too many patients and not enough inoculations.
Connections for Business, a South Florida IT service provider, was spending unnecessary money on labor and overhead. Without a business management platform to assist in developing their systems and processes, that job fell on the team, and the team only. Billing was inaccurate and taking 40-50 hours a month to complete.
Direction from a solution provider with expertise in forecasting, packaging, labeling and distribution along with services of an IRT provider solves drug shortage challenge.
Last year, physicists at MIT, the University of Vienna, and elsewhere provided strong support for quantum entanglement, the seemingly far-out idea that two particles, no matter how distant from each other in space and time, can be inextricably linked, in a way that defies the rules of classical physics.
The US biotech company aims to have four groundbreaking gene therapies launched by 2022 – with the promise of lives transformed in each of these rare blood diseases – and realistic hope of a cure for many patients.
Bioclinica®, the world-leading provider of scientific- and technology-enabled solutions for clinical research, recently announces its ICSR team delivered quality and consistency in Individual Case Safety Report (ICSR) processing while crossing the one million case milestone in 2017 –setting a new Company record, while enabling several ‘Top 20’ drug safety operations clients to meet their global regulatory requirements for safety reporting.
Invuity, Inc. (NASDAQ: IVTY), a leading medical technology company focused on advanced surgical devices to enable better visualization, today announced it has entered into a definitive agreement with Stryker Corporation (NYSE:SYK), pursuant to which Stryker will acquire all of the outstanding shares of Invuity for $7.40 per share in cash, implying a total equity value of approximately $190 million.
Researchers at the University of Sheffield have solved a key puzzle in quantum physics that could help to make data transfer totally secure.
